Phenoxodiol is primarily investigated for its potential in cancer treatment, particularly as an anticancer agent targeting resistant tumor cells. It functions by inhibiting the activity of survival proteins in cancer cells, such as those in the X-linked inhibitor of apoptosis (XIAP) family, making tumor cells more susceptible to chemotherapy and radiation. It has been studied in clinical trials for ovarian, prostate, and other solid tumors, especially in cases where cancer has become resistant to conventional therapies. Phenoxodiol may help reverse drug resistance by modulating cellular pathways involved in apoptosis, thereby enhancing the effectiveness of existing anticancer drugs. Research also suggests it may have a role in sensitizing cancer cells to immune-based treatments. Despite promising preclinical results, its clinical use remains under investigation.